CC BY 4.0 · Rev Bras Ginecol Obstet 2023; 45(02): 074-081
DOI: 10.1055/s-0042-1757956
Original Article
Oncology

Germline Mutations Landscape in a Cohort of the State of Minas Gerais, Brazil, in Patients Who Underwent Genetic Counseling for Gynecological and Breast Cancer

Cenário de mutações germinativas em uma coorte do estado de Minas Gerais, Brasil, em pacientes submetidas ao aconselhamento genético para câncer ginecológico e de mama
Camila Martins de Carvalho 
1   Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
,
Letícia da Conceição Braga 
2   OncoTag Desenvolvimento de Produtos e Serviços para Saúde Humana, Belo Horizonte, MG, Brazil
3   Translational Research Laboratory in Oncology, Instituto Mário Penna-Ensino, Pesquisa e Inovação, Belo Horizonte, MG, Brazil
,
Luciana Maria Silva 
2   OncoTag Desenvolvimento de Produtos e Serviços para Saúde Humana, Belo Horizonte, MG, Brazil
4   Cell Biology Service, Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil
,
Anisse Marques Chami 
5   School of Medicine, Campus Botucatu, Universidade Estadual Paulista, Belo Horizonte, MG, Brazil
,
Agnaldo Lopes da Silva Filho 
1   Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
5   School of Medicine, Campus Botucatu, Universidade Estadual Paulista, Belo Horizonte, MG, Brazil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective The present study evaluated the profile of germline mutations present in patients who underwent genetic counseling for risk assessment for breast cancer (BC), ovarian cancer (OC), and endometrial cancer (EC) with a possible hereditary pattern.

Methods Medical records of 382 patients who underwent genetic counseling after signing an informed consent form were analyzed. A total of 55.76% of patients (213/382) were symptomatic (personal history of cancer), and 44.24% (169/382) were asymptomatic (absence of the disease). The variables analyzed were age, sex, place of birth, personal or family history of BC, OC, EC, as well as other types of cancer associated with hereditary syndromes. The Human Genome Variation Society (HGVS) nomenclature guidelines were used to name the variants, and their biological significance was determined by comparing 11 databases.

Results We identified 53 distinct mutations: 29 pathogenic variants, 13 variants of undetermined significance (VUS), and 11 benign. The most frequent mutations were BRCA1 c.470_471delCT, BRCA1 c.4675 + 1G > T, and BRCA2 c.2T> G. Furthermore, 21 variants appear to have been described for the first time in Brazil. In addition to BRCA1/2 mutations, variants in other genes related to hereditary syndromes that predispose to gynecological cancers were found.

Conclusion This study allowed a deeper understanding of the main mutations identified in families in the state of Minas Gerais and demonstrates the need to assess the family history of non-gynecological cancer for risk assessment of BC, OC, and EC. Moreover, it is an effort that contributes to population studies to evaluate the cancer risk mutation profile in Brazil.

Resumo

Objetivo O presente estudo avaliou o perfil de mutações germinativas presentes em pacientes submetidas a aconselhamento genético para avaliação de risco para câncer de mama (CM), câncer de ovário (OC) e câncer de endométrio (CE) com possível padrão hereditário.

Métodos Foram analisados os prontuários de 382 pacientes que realizaram aconselhamento genético após consentimento informado. Um total de 55,76% dos pacientes (213/382) eram sintomáticos (história pessoal de câncer), e 44,24% (169/382) eram assintomáticos (ausência da doença). As variáveis analisadas foram idade, sexo, naturalidade, história pessoal ou familiar de CM, OC, CE bem como outros tipos de câncer associados a síndromes hereditárias. As diretrizes de nomenclatura da Human Genome Variation Society (HGVS) foram usadas para nomear as variantes e seu significado biológico foi determinado pela comparação de 11 bancos de dados.

Resultados Identificamos 53 mutações distintas: 29 variantes patogênicas, 13 variantes de significado indeterminado e 11 benignas. As mutações mais frequentes foram BRCA1 c.470_471delCT, BRCA1 c.4675 + 1G > T e BRCA2 c.2T > G. Além disso, 21 variantes parecem ter sido descritas pela primeira vez no Brasil. Além das mutações BRCA1/2, foram encontradas variantes em outros genes relacionados a síndromes hereditárias que predispõem a cânceres ginecológicos.

Conclusão Este estudo permitiu conhecer melhor as principais mutações identificadas nas famílias do estado de Minas Gerais e demonstra a necessidade de avaliar a história familiar de câncer não ginecológico para avaliação do risco de CM, OC e CE. Além disso, é um esforço que contribui com estudos populacionais para avaliar o perfil de mutações de risco para câncer no Brasil.

Keywords

germline variants - genetic counseling - gynecological cancer risk - hereditary syndromes

Palavras-chave

variantes de linhagem germinativa - aconselhamento genético - risco de câncer ginecológico - síndromes hereditárias

Contributions

All authors contributed equally to this work offering (1) substantial contributions to conception and design, data collection, or analysis and interpretation of data; (2) article writing or relevant critical review of the intellectual content, and (3) final approval of the version to be published.




Publication History

Received: 26 April 2022

Accepted: 17 August 2022

Article published online:
28 March 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Search in Google Scholar
  • 2 Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019 [cited 2022 Feb 12]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf
    PubMed
  • 3 Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat 2016; 160 (03) 393-410
    CrossrefPubMedSearch in Google Scholar
  • 4 Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020; 38 (11) 1222-1245
    CrossrefPubMedSearch in Google Scholar
  • 5 Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 2017; 217 (05) 512-521
    CrossrefPubMedSearch in Google Scholar
  • 6 Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J. et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012; 133 (03) 1125-1130
    CrossrefPubMedSearch in Google Scholar
  • 7 Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. BioMed Res Int 2013; 2013: 747318
    CrossrefPubMedSearch in Google Scholar
  • 8 Ngeow J, Sesock K, Eng C. Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 2017; 165 (01) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 9 Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J. et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 2017; 3 (09) 1190-1196
    CrossrefPubMedSearch in Google Scholar
  • 10 Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT. et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol 2017; 146 (02) 217-224
    CrossrefPubMedSearch in Google Scholar
  • 11 Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P. et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. J Natl Compr Canc Netw 2020; 18 (04) 380-391
    CrossrefPubMedSearch in Google Scholar
  • 12 Carnevali I, Riva C, Chiaravalli AM, Sahnane N, Di Lauro E, Viel A. et al. Inherited cancer syndromes in 220 Italian ovarian cancer patients. Cancer Genet 2019; 237: 55-62
    CrossrefPubMedSearch in Google Scholar
  • 13 Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P. Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil. JCO Glob Oncol 2020; 6: 439-452
    CrossrefPubMedSearch in Google Scholar
  • 14 Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 2017; 31: 224-232
    CrossrefPubMedSearch in Google Scholar
  • 15 Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A. et al; EMBRACE, GEMO Study Collaborators, HEBON. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 2018; 39 (05) 593-620
    CrossrefPubMedSearch in Google Scholar
  • 16 Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat 2015; 149 (01) 223-227
    CrossrefPubMedSearch in Google Scholar
  • 17 Palmero EI, Carraro DM, Alemar B, Moreira MA, Ribeiro-Dos-Santos A, Abe-Sandes K. et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep 2018; 8 (01) 9188
    CrossrefPubMedSearch in Google Scholar
  • 18 Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN. et al. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS One 2012; 7 (09) e43994
    CrossrefPubMedSearch in Google Scholar
  • 19 Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M. et al. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet 2018; 63 (04) 447-457
    CrossrefPubMedSearch in Google Scholar
  • 20 Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 2010; 1 (03) 397-412
    CrossrefPubMedSearch in Google Scholar
  • 21 Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE. et al. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 2016; 7 (49) 80465-80481
    CrossrefPubMedSearch in Google Scholar
  • 22 Felicio PS, Alemar B, Coelho AS, Berardinelli GN, Melendez ME, Lengert AV. et al. Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast. Cancer Genet 2018; 228-229: 93-97
    CrossrefPubMedSearch in Google Scholar
  • 23 Hahn EC, Bittar CM, Vianna FSL, Netto CB, Biazús JV, Cericatto R. et al. TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients. PLoS One 2018; 13 (12) e0209934
    CrossrefPubMedSearch in Google Scholar
  • 24 Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F. et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010; 31 (02) 143-150
    CrossrefPubMedSearch in Google Scholar
  • 25 Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L. et al. The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet 2016; 209 (1-2): 50-52
    CrossrefPubMedSearch in Google Scholar
  • 26 Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O. MutYH mutation carriers have increased breast cancer risk. Cancer 2012; 118 (08) 1989-1993
    CrossrefPubMedSearch in Google Scholar
  • 27 Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD. et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 2011; 129 (09) 2256-2262
    CrossrefPubMedSearch in Google Scholar
  • 28 Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer 2015; 15: 936
    CrossrefPubMedSearch in Google Scholar
  • 29 Chern JY, Lee SS, Frey MK, Lee J, Blank SV. The influence of BRCA variants of unknown significance on cancer risk management decision-making. J Gynecol Oncol 2019; 30 (04) e60
    CrossrefPubMedSearch in Google Scholar